Evaluation of Biomarkers Levels in Gingival Crevicular Fluid, Saliva and Serum for Different Periodontal Diseases

Akdeniz University

Status: Completed

Conditions: Mouth Diseases; Periodontal Diseases; Periodontal Inflammation

Treatments: Diagnostic Test: Saliva Obtaining; Diagnostic Test: Serum obtaining; Diagnostic Test: GCF obtaining

Study type: Interventional

Funder types: Other

Identifiers

NCT05435131

Hkorkmaz

Details and patient eligibility

About

The aim of this study is; detection of interleukin(IL)-38, IL-36 gamma(γ) , IL-17 and matrix metalloproteinase(MMP)-9 levels in gingival crevicular fluid (GCF), saliva and serum samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples were obtained from 90 systemically healthy non-smoker individuals with periodontitis (P, n=30), gingivitis(G, n=30) and healthy periodontium (S, n=30). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine IL-38, IL-36γ, IL-17 and MMP-9 levels in the biological samples.

Enrollment: 90 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.)
• At least twenty permanent teeth in the mouth
• Non-smoker
• No medication for continuous use
• Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months.
• Not in pregnancy or lactation period.
• For the periodontitis group that has not received periodontal treatment in the last 6 months

Exclusion criteria

• Any oral or systemic disease
• Regularly using a systemic medication
• During pregnancy or lactation
• Received periodontal treatment within the last 6 months.
• Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months
• Smokers

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 5 patient groups

Periodontal Health

Experimental group

Description:

Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.

Treatment:

Diagnostic Test: Saliva Obtaining

Diagnostic Test: Serum obtaining

Diagnostic Test: GCF obtaining

Gingivitis

Experimental group

Description:

Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.

Treatment:

Diagnostic Test: Saliva Obtaining

Diagnostic Test: Serum obtaining

Diagnostic Test: GCF obtaining

Stage II grade B Periodontitis

Experimental group

Description:

Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.

Treatment:

Diagnostic Test: Saliva Obtaining

Diagnostic Test: Serum obtaining

Diagnostic Test: GCF obtaining

Stage III grade B Periodontitis

Experimental group

Description:

Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.

Treatment:

Diagnostic Test: Saliva Obtaining

Diagnostic Test: Serum obtaining

Diagnostic Test: GCF obtaining

Stage III grade C Periodontitis

Experimental group

Description:

Full-mouth clinical periodontal measurements recorded and GCF, saliva serum obtained.

Treatment:

Diagnostic Test: Saliva Obtaining

Diagnostic Test: Serum obtaining

Diagnostic Test: GCF obtaining